Haha my post yesterday was timely. Looks like a net positive...

Haha my post yesterday was timely. Looks like a net positive year with no reason to go backwards, considering the locked in contracts.

▪ FY22 Total Revenue of $14.3m; 215% growth on FY21 ($4.5m), 3.8% increase on Prospectus forecast
▪ Pro forma EBITDA of $1.45m; +$2.2m growth on FY21 (-$0.7m), 57% increase on Prospectus forecast
▪ Average PhotonAssayTM unit Utilisation of 66% across deployed assets; an increase on 41.6% in FY21
▪ Operating cash flow positive, with cash balance of $92m as at 30 June 2022
▪ Return on Invested Capital (ROIC) increasing from 34% to 47% with the addition of 15 new agreements since IPO and correspondingly higher unit TCV

Also worth noting there's $90M+ cash on hand end-June! That's a huge amount of capital for growth, considering they're making money already.

GLTAH